We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Wyeth received an approvable letter from the FDA for its postmenopausal osteoporosis prevention product, bazedoxifene, April 24. Bazedoxifene's brand name, Viviant, is still under FDA review. Read More
A pathway for creating and marketing generic biologics could help health plan sponsors and patients save $71 billion over the next 10 years, according to an Express Scripts report. Read More
Amgen plans to announce results from an Aranesp small-cell lung cancer clinical trial when the firm reports first quarter earnings April 23, the company announced. Read More
U.S. sales of Johnson & Johnson's (J&J) erythropoiesis-stimulating agent (ESA) Procrit remained steady during the fourth quarter of 2007 despite recent drug safety issues associated with the use of ESAs. Read More
Eli Lilly's net income plummeted 39.1 percent to $508.7 million in the first quarter of fiscal 2007, from $834.8 million in the same period last year, despite worldwide sales growth of 14 percent to $4.23 billion. Read More
Teva Pharmaceutical’s multiple sclerosis (MS) agent Copaxone is a better treatment for patients with relapsing-remitting MS compared with interferon beta drug products, a recent study found.
Magnetic resonance imaging (MRI) can detect cancer in the second, or contralateral, breast in women with breast cancer, even when it is missed by mammography and clinical examination during the initial breast-cancer diagnosis, a study in the March 29 issue of the New England Journal of Medicince says.
Stents have not been successful enough in treating chronic total artery blockage, or chronic total occlusion (CTO), leaving room for new techniques and devices, a recent study says.